Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
about
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and MassAdverse Effects of GLP-1 Receptor Agonistsβ-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic conditionHuman Islet Morphology Revisited: Human and Rodent Islets Are Not So Different After AllIncretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials.Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.Extra-pancreatic effects of incretin-based therapies.Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.A review of gliptins for 2014.Potential side effects to GLP-1 agonists: understanding their safety and tolerability.Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.An updated review on cancer risk associated with incretin mimetics and enhancers.Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!GLP-1 based therapies: clinical implications for gastroenterologists.Immunohistochemical assessment of glucagon-like peptide 1 receptor (GLP-1R) expression in the pancreas of patients with type 2 diabetes.Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine PancreasHistological changes in endocrine and exocrine pancreatic tissue from patients exposed to incretin-based therapies.Sitagliptin increases acute pancreatitis risk within 2 years of its initiation: A retrospective cohort analysis of the National Health Insurance database in Taiwan.Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys.GLP-1 receptor agonists in type 1 diabetes: a proof-of-concept approach.The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys.Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial.Effects of Linagliptin on Pancreatic α Cells of Type 1 Diabetic Mice.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions.
P2860
Q26749089-65A08A7C-CE1E-4392-AD41-678EE1981E26Q26801346-112D39D0-DC97-4259-9ED4-F7AB9298AE8AQ33570085-EFAF2A03-10D7-4722-8BF7-A3CE0D9B2456Q33824522-6D7F64F6-57D0-42A1-B646-DCB578960A12Q34780873-BAA14489-4E08-4F4E-96C8-11DE55D3C75AQ35184904-6A71C25C-655D-4BA2-90BD-9E8C65FD556DQ35932755-27298E21-21E3-4B97-A51F-67F2AEF99634Q37427294-8C1B393A-BEAB-4E09-80A9-F8C0C84FB138Q37517909-D68A661E-58AE-40A0-82D9-88A4B8057D0FQ38194069-B60B3E1A-2CF1-4BBF-9F4E-BB03BDC56617Q38255715-4C5E55CA-EA44-4EF7-AB92-AC4710546C5DQ38264360-387B963E-712E-405F-A49F-25F0A4A00EC7Q38266290-B21513A1-63C0-4B54-84E3-97B536F547E7Q38286444-B20DCA35-18E3-4A73-99FF-EC567A95AD06Q38335751-BB35D602-65A4-42C5-884E-C0EF565865E6Q38388920-ACCC7846-7907-4354-B980-1A3E2467F821Q38601929-864EAF23-7F1F-43ED-8D9B-4788133C4522Q38703292-C50B8406-8262-458E-9EC3-3B96135E8A5BQ39017198-CE5FFB59-80E7-45D5-AEC3-0EFBC80CAF54Q39052404-93ABBE84-F607-4B53-BFDA-3008987CE81BQ39469799-0C3E84FF-5C4A-49A6-8E6C-AD4416B3947FQ40478079-D972740F-2D0A-468F-B408-6C4D915250E7Q40852125-672F8F7F-2AD7-446A-A798-4B65ACEED377Q41465810-480EB55D-75F8-47B7-A2DC-330F57DCDC99Q45778975-809C4823-1A30-4473-89C0-0FE002623A93Q48007843-B8913082-D3EC-46AE-9E68-4C12238779BFQ52741508-FC122DAC-92ED-40EE-A000-412B6FCABE80Q52780711-497A01D0-B9E3-41B6-B5E2-0AC0D871797AQ55380220-D8EA3E5E-D3B7-4871-9F5B-7A0001299237
P2860
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Reanalysis of study of pancrea ...... : methodological deficiencies.
@en
Reanalysis of study of pancrea ...... : methodological deficiencies.
@nl
type
label
Reanalysis of study of pancrea ...... : methodological deficiencies.
@en
Reanalysis of study of pancrea ...... : methodological deficiencies.
@nl
prefLabel
Reanalysis of study of pancrea ...... : methodological deficiencies.
@en
Reanalysis of study of pancrea ...... : methodological deficiencies.
@nl
P2093
P2860
P356
P1476
Reanalysis of study of pancrea ...... : methodological deficiencies.
@en
P2093
P A In't Veld
S Bonner-Weir
P2860
P304
P356
10.1111/DOM.12257
P577
2014-01-29T00:00:00Z